អង់ទីប៊ីយ៉ូទិកធន់ ជាពិសេសដោយបាក់តេរី Gram-negative ស្ទើរតែបានបង្កើតវិបត្តិដូចស្ថានភាព។ ថ្នាំអង់ទីប៊ីយោទិចប្រលោមលោក Zosurabalpin (RG6006) បង្ហាញពីការសន្យា។ វាត្រូវបានគេរកឃើញថាមានប្រសិទ្ធភាពប្រឆាំងនឹងបាក់តេរីក្រាមអវិជ្ជមាន CRAB ដែលធន់នឹងថ្នាំក្នុងការសិក្សាមុនគ្លីនិក។
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of ថ្នាំ antibiotics to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of អង់ទីប៊ីយ៉ូទិក ការតស៊ូ។
អាស៊ីតអាមីណូតូបាប៊ីប៊ីននី is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available ថ្នាំ antibiotics. There is an urgent need for an effective អង់ទីប៊ីយ៉ូទិក against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective អង់ទីប៊ីយ៉ូទិក. A progress towards this goal has been reported.
Scientists have identified a novel class of ថ្នាំ antibiotics namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
Zosurabalpin (RG6006) គឺជា អង់ទីប៊ីយ៉ូទិក candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-គ្លីនិក trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame អង់ទីប៊ីយ៉ូទិក-resistance mechanism of CARB suggesting Zosurabalpin មានសក្តានុពល។
Hence, human គ្លីនិក trials have been initiated to check for safety and efficacy Zosurabalpin ក្នុងការព្យាបាលការឆ្លងមេរោគរាតត្បាតដែលបណ្តាលមកពី CRAB ។
***
ឯកសារយោង:
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel អង់ទីប៊ីយ៉ូទិក class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- Hawser S., et al 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against គ្លីនិក Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
